173 related articles for article (PubMed ID: 34035113)
21. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
[TBL] [Abstract][Full Text] [Related]
23. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
[TBL] [Abstract][Full Text] [Related]
24. COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
Klupsch K; Baeriswyl V; Scholz R; Dannenberg J; Santimaria R; Senn D; Kage E; Zumsteg A; Attinger-Toller I; von der Bey U; König-Friedrich S; Dupuy F; Lembke W; Albani C; Wendelspiess S; Dinkel L; Saro D; Hepler RW; Laszlo GS; Gudgeon CJ; Bertschinger J; Brack S; Walter RB
Leukemia; 2019 Mar; 33(3):805-808. PubMed ID: 30206306
[No Abstract] [Full Text] [Related]
25. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
26. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
[TBL] [Abstract][Full Text] [Related]
27. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
28. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
Zeng Z; Roobrouck A; Deschamps G; Bonnevaux H; Guerif S; De Brabandere V; Amara C; Dejonckheere E; Virone-Oddos A; Chiron M; Konopleva M; Dullaers M
Blood Adv; 2024 May; 8(9):2059-2073. PubMed ID: 38266153
[TBL] [Abstract][Full Text] [Related]
29. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
Hoseini SS; Espinosa-Cotton M; Guo HF; Cheung NV
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239418
[TBL] [Abstract][Full Text] [Related]
30. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
31. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
32. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
[TBL] [Abstract][Full Text] [Related]
33. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
[TBL] [Abstract][Full Text] [Related]
34. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
35. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
36. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Nair-Gupta P; Diem M; Reeves D; Wang W; Schulingkamp R; Sproesser K; Mattson B; Heidrich B; Mendonça M; Joseph J; Sendecki J; Foulk B; Chu G; Fink D; Jiao Q; Wu SJ; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Mar; 4(5):906-919. PubMed ID: 32150609
[TBL] [Abstract][Full Text] [Related]
37. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
Sutherland MK; Yu C; Lewis TS; Miyamoto JB; Morris-Tilden CA; Jonas M; Sutherland J; Nesterova A; Gerber HP; Sievers EL; Grewal IS; Law CL
MAbs; 2009; 1(5):481-90. PubMed ID: 20065652
[TBL] [Abstract][Full Text] [Related]
38. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
39. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I
Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494
[TBL] [Abstract][Full Text] [Related]
40. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
